In colon cancer patients, the 5-year DFS was 73.83% (95% CI, 64.15%-83.51%) for patients without CB2 expression versus 48.68% (95% CI, 28.81%-68.55%) for patients with CB2 expression (p = 0.018). This evidence concerns the gene CNR2 and malignant colon neoplasm.